Bernie Sanders Questions Novo Nordisk CEO on High Prices of Obesity Drugs
Wednesday, 25 September 2024, 17:01
Bernie Sanders on Drug Pricing
During a recent Senate hearing, Bernie Sanders brought attention to the issue of drug pricing, particularly regarding Novo Nordisk's obesity drugs such as Ozempic and Wegovy. Novo Nordisk CEO Lars Fruergaard Jørgensen faced intense questioning about the affordability of GLP-1 therapies. With the obesity epidemic in the US intensifying, there is a pressing need to address insulin price manipulation and the role of pharmacy benefit managers.
Understanding Drug Pricing Dynamics
- Impacts of Medicare drug price negotiations
- Concerns over PBMs and their influence on drug prices
- The ongoing ozempic price debate and its ramifications
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.